• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[血小板 - 形态学、形状改变因子及血小板凝集因子。血栓性血小板减少性紫癜研究小组]

[Platelets-morphology, shape changing factor, and platelet agglutinating factor. TTP Research Group].

作者信息

Hattori A, Tatewaki W, Fuse I, Shibata A

机构信息

Sado General Hospital.

出版信息

Nihon Rinsho. 1993 Jan;51(1):122-8.

PMID:8433504
Abstract

The morphology of circulating platelets in thrombotic thrombocytopenic purpura (TTP) was studied, and basic mechanism of the characteristic shape abnormality found in TTP was investigated in in vitro condition. The platelet shape was spineless sphere (spherical platelets without pseudopods), and shape change persisted 2 months after remission. This type of platelets were produced by long term of activation of normal resting platelets by several agonists except ADP, and induced by dysfunction of both microtubules and microfilaments. These suggest that the shape change in TTP is not specific, but a good parameter for the activity of TTP. PAF activity by the method of Kelton et al. (1984) was detected in only 1 out of 30 samples from 10 patients. PSCF activity was found in 9 out of 29 samples from 10 patients independently from disease activity. Both activities does not reflect the activity of TTP.

摘要

对血栓性血小板减少性紫癜(TTP)患者循环血小板的形态进行了研究,并在体外条件下探究了TTP中发现的特征性形状异常的基本机制。血小板形状为无棘球(无伪足的球形血小板),且形状改变在缓解后持续2个月。这种类型的血小板是由除ADP外的几种激动剂长期激活正常静息血小板产生的,并由微管和微丝功能障碍诱导产生。这些表明TTP中的形状改变并非特异性的,而是TTP活性的一个良好参数。采用Kelton等人(1984年)的方法检测,10例患者的30份样本中仅有1份检测到血小板活化因子(PAF)活性。在10例患者的29份样本中有9份检测到血小板第三因子(PSCF)活性,且与疾病活动无关。这两种活性均不能反映TTP的活性。

相似文献

1
[Platelets-morphology, shape changing factor, and platelet agglutinating factor. TTP Research Group].[血小板 - 形态学、形状改变因子及血小板凝集因子。血栓性血小板减少性紫癜研究小组]
Nihon Rinsho. 1993 Jan;51(1):122-8.
2
[Thrombotic thrombocytopenic purpura (TTP) with a remission following splenectomy after the failure of antiplatelet therapy and plasmapheresis].抗血小板治疗和血浆置换失败后行脾切除术缓解的血栓性血小板减少性紫癜(TTP)
Rinsho Ketsueki. 1984 Oct;25(10):1699-704.
3
[Purification and some properties of platelet aggregating protein (PAP) from the plasma of a patient with thrombotic thrombocytopenic purpura].[来自一名血栓性血小板减少性紫癜患者血浆的血小板聚集蛋白(PAP)的纯化及某些特性]
Zhonghua Yi Xue Za Zhi. 1989 Jul;69(7):382-4, 28.
4
The platelet aggregating factor(s) of thrombotic thrombocytopenic purpura.血栓性血小板减少性紫癜的血小板聚集因子
Prog Clin Biol Res. 1990;337:141-9.
5
Binding of platelet agglutinating protein p37 from the plasma of a patient with thrombotic thrombocytopenic purpura to human platelets.血栓性血小板减少性紫癜患者血浆中血小板凝集蛋白p37与人血小板的结合。
Thromb Haemost. 1991 Jan 23;65(1):96-101.
6
Morphological platelet anomalies in thrombotic thrombocytopenic purpura.血栓性血小板减少性紫癜中的血小板形态异常
Acta Haematol. 1982;67(2):119-23. doi: 10.1159/000207037.
7
Inhibition of platelet-aggregating activity in thrombotic thrombocytopenic purpura plasma by normal adult immunoglobulin G.正常成人免疫球蛋白G对血栓性血小板减少性紫癜血浆中血小板聚集活性的抑制作用。
J Clin Invest. 1984 Feb;73(2):548-55. doi: 10.1172/JCI111242.
8
[Thrombotic thrombocytopenic purpura--recent development of TTP study].[血栓性血小板减少性紫癜——TTP研究的最新进展]
Nihon Rinsho. 1993 Jan;51(1):114-6.
9
The aptamer ARC1779 blocks von Willebrand factor-dependent platelet function in patients with thrombotic thrombocytopenic purpura ex vivo.适体 ARC1779 可阻断体外血栓性血小板减少性紫癜患者 von Willebrand 因子依赖性血小板功能。
Transfusion. 2010 May;50(5):1079-87. doi: 10.1111/j.1537-2995.2009.02554.x. Epub 2010 Jan 8.
10
Thrombotic thrombocytopenic purpura and the haemolytic-uraemic syndrome: evolving concepts of pathogenesis and therapy.血栓性血小板减少性紫癜与溶血尿毒综合征:发病机制与治疗的演变概念
Clin Haematol. 1986 May;15(2):413-42.